Zacks Rating on Baxter International (BAX)

Baxter International (BAX) : 11 analysts are covering Baxter International (BAX) and their average rating on the stock is 2.94, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 9 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Baxter International (BAX) : The consensus price target for Baxter International (BAX) is $50.29 for the short term with a standard deviation of $4.79. The most optimist securities analyst among the 7 who monitor the stock believes that the stock can reach $60, however, the pessimist price target for the company is $46.


Baxter International Inc. has dropped 0.54% in the last five trading days, however, the shares have posted positive gains of 4.08% in the last 4 weeks. Baxter International Inc. is up 10.23% in the last 3-month period. Year-to-Date the stock performance stands at 26.51%. Baxter International (NYSE:BAX): The stock was completely flat for the day, closing at $47.98 on Tuesday. The flat closing masks the intraday volatility in the stock. After opening at $48.07, the stock touched an intraday high of $48.35 and a low of $47.94. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $47.98. The total trading volume on Tuesday was 2,280,837.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.